ZYLM (Central Asia Lumeichun Biotechnology) Debt-to-EBITDA : (As of Jun. 2026)

Central Asia Lumeichun Biotechnology  (OTCPK:ZYLM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Central Asia Lumeichun Biotechnology Debt-to-EBITDA Related Terms

The historical data trend for Central Asia Lumeichun Biotechnology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Asia Lumeichun Biotechnology Debt-to-EBITDA Chart

Central Asia Lumeichun Biotechnology Annual Data
	Trend	Mar07	Mar08	Mar09	Mar10	Mar11	Mar14	Mar15	Aug23	Dec24	Dec25
Debt-to-EBITDA		Get a 7-Day Free Trial					-	-	-	-	-

Central Asia Lumeichun Biotechnology Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun13	Jun15	Sep15	Dec15	Nov22	Feb23	May23	Aug23	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-	-	-

ZYLM vs RHE, DVCR, FVE: Debt-to-EBITDA Comparison

For the Farm Products subindustry, Central Asia Lumeichun Biotechnology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Central Asia Lumeichun Biotechnology Debt-to-EBITDA vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Central Asia Lumeichun Biotechnology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Central Asia Lumeichun Biotechnology's Debt-to-EBITDA falls into.

Central Asia Lumeichun Biotechnology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Central Asia Lumeichun Biotechnology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Central Asia Lumeichun Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Central Asia Lumeichun Biotechnology Business Description